Ipsen has reached an agreement to buy fellow French firm ImCheck Therapeutics in a deal that could be worth up to €1 billion ($1.16 billion), adding an antibody-based therapy for acute myeloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback